Deleted Tweets From Scott Gottlieb, R-D.C.

In #shutdown, we're looking at risk across our entire portfolio, and shifting resources to areas most critical to protecting consumers, to the extent law allows. That includes shifting some pre-market drug review resources to post market drug safety work: https://t.co/9kPEihskdD

There are no recommendations to avoid any romaine on the market. Industry removed potentially contaminated product and is taking steps to provide info on romaine’s source on packaging, point of sale signs, etc. We’ll continue sharing #FDA investigation updates.

@juliaoftoronto Our Coordinated Outbreak Response and Evaluation (CORE) teams that engage in outbreak response are stood up and available. Responding to outbreaks is a top priority and an excepted activity. Consumer protection is our top priority.

#FDA teams have collected environmental samples and are working with growers to pinpoint when and how the romaine lettuce became contaminated. We believe that the findings of this ongoing investigation will help to prevent future outbreaks in leafy greens. https://t.co/T2JA9vuwDP

#FDA continues to be concerned about branded companies creating confusion about the safety and effectiveness of biosimilars and we’ll take action if we determine a company is deliberately misleading the public about the safety of these important products. https://t.co/PNSI9nN0qM

The new news was that we’re standing up high risk inspections. This is a departure from practices during past shutdowns, and part of our continuing effort at #FDA to focus our resources on areas of highest potential risk to consumers during the shutdown. QT @ddiamond: Yesterday’s viral stories about FDA and food inspections shouldn’t come as a surprise to POLITICO readers or listen… https://t.co/MSrFCugGx9)

#FDA is developing a new office focused on drug development science. The goal is to advance key areas of new science that's can modernize and improve the predictability of drug development, so we can learn more about safety and efficacy more efficiently https://t.co/A3q8JvSeJt

#Flu activity is picking up. It looks like a predominant H1N1 season, which tends to peak late. There's a small amount of H3N2 activity, mostly in South East. The vaccine is generally good against H1N1 strains, with 60% effectiveness or more. It's not too late to get vaccinated. https://t.co/BTQuML8P7I

Congratulations to our colleague @AnandShahMD on this new post. Anand has dedicated his career to service, innovation, and advancing the public health; along the way, carving a path marked above everything else, by dedication to families and patient care https://t.co/mdLCNCrqdQ

FDA looks to restart safety inspections for risky foods amid shutdown - POLITICO https://t.co/90QGdw5Iw9

Today, my #FDA colleagues who are very important to our mission yet find themselves furloughed, and many who are excepted and continue to work, will not get their usual pay. I deeply regret these hardships. And I admire very much their continued dedication to our special mission. https://t.co/3CSAqxzN9U

#FDA will issue within a month the guidance implementing the policy steps we announced in November to limit youth access and appeal of these products. But if these trends don’t reverse sharply and rapidly, I fear the consensus supporting these products for adults will disappear.

RT @FDATobacco: Tobacco retailers are invited to watch FDA’s “Tips for Retailers” video which shares important information on resources available to help prevent the sale of tobacco products to minors. https://t.co/zEzTwjPBoc

These trends, if they continue into 2019 which I believe they are, represent an existential threat to the entire product category. The irresponsible actions of some product developers, allowing this use to continue till now, puts the entire opportunity at risk for adult smokers. https://t.co/PclBnSrQ4M QT @NEJM: )

My note to #FDA colleagues today. For many who are furloughed, and can’t check email, I share it here and on our website. On this day when many will receive no paycheck, we’re reminded of the special mission that binds us together in challenging work and difficult circumstances. https://t.co/SO4pB5Lacq

I'm proud of the work done by FDA’s Generic Drug Program in ensuring Americans have access to high quality, lower cost, safe and effective generics. I’m committed to continuing to advance policies aimed at making it more efficient to bring generic competition to the market. https://t.co/BTAHBtLaSj

In calendar years 2017-2018, #FDA approved or tentatively approved a total of 2,048 generic drugs, with two months in Fall 2018 seeing record-breaking generic drug approval totals. https://t.co/HNXuB2tCCs https://t.co/vkJLkOD4z4

THREAD: Update on Shutdown - Questions are being raised around FDA’s efforts to support device safety during the partial lapse in funding, especially with respect to post-market surveillance. I want to provide some background:

First, I want to reassure everyone that while it’s not business as usual at the agency, we are continuing to prioritize our device safety work both before AND after medical devices come to market.

With respect to post-market efforts, the agency is currently monitoring ALL medical device adverse events it receives, looking for concerns and signals that need to be addressed. If we find issues, we can and will act to protect Americans from imminent threats to health.

In #shutdown, we're looking at risk across our entire portfolio, and shifting resources to areas most critical to protecting consumers, to the extent law allows. That includes shifting some pre-market drug review resources to post market drug safety work: https://t.co/9kPEihskdD

There are no recommendations to avoid any romaine on the market. Industry removed potentially contaminated product and is taking steps to provide info on romaine’s source on packaging, point of sale signs, etc. We’ll continue sharing #FDA investigation updates.

@juliaoftoronto Our Coordinated Outbreak Response and Evaluation (CORE) teams that engage in outbreak response are stood up and available. Responding to outbreaks is a top priority and an excepted activity. Consumer protection is our top priority.

#FDA teams have collected environmental samples and are working with growers to pinpoint when and how the romaine lettuce became contaminated. We believe that the findings of this ongoing investigation will help to prevent future outbreaks in leafy greens. https://t.co/T2JA9vuwDP

#FDA continues to be concerned about branded companies creating confusion about the safety and effectiveness of biosimilars and we’ll take action if we determine a company is deliberately misleading the public about the safety of these important products. https://t.co/PNSI9nN0qM

The new news was that we’re standing up high risk inspections. This is a departure from practices during past shutdowns, and part of our continuing effort at #FDA to focus our resources on areas of highest potential risk to consumers during the shutdown. QT @ddiamond: Yesterday’s viral stories about FDA and food inspections shouldn’t come as a surprise to POLITICO readers or listen… https://t.co/MSrFCugGx9)

#FDA is developing a new office focused on drug development science. The goal is to advance key areas of new science that's can modernize and improve the predictability of drug development, so we can learn more about safety and efficacy more efficiently https://t.co/A3q8JvSeJt

#Flu activity is picking up. It looks like a predominant H1N1 season, which tends to peak late. There's a small amount of H3N2 activity, mostly in South East. The vaccine is generally good against H1N1 strains, with 60% effectiveness or more. It's not too late to get vaccinated. https://t.co/BTQuML8P7I

Congratulations to our colleague @AnandShahMD on this new post. Anand has dedicated his career to service, innovation, and advancing the public health; along the way, carving a path marked above everything else, by dedication to families and patient care https://t.co/mdLCNCrqdQ

FDA looks to restart safety inspections for risky foods amid shutdown - POLITICO https://t.co/90QGdw5Iw9

Today, my #FDA colleagues who are very important to our mission yet find themselves furloughed, and many who are excepted and continue to work, will not get their usual pay. I deeply regret these hardships. And I admire very much their continued dedication to our special mission. https://t.co/3CSAqxzN9U

#FDA will issue within a month the guidance implementing the policy steps we announced in November to limit youth access and appeal of these products. But if these trends don’t reverse sharply and rapidly, I fear the consensus supporting these products for adults will disappear.

RT @FDATobacco: Tobacco retailers are invited to watch FDA’s “Tips for Retailers” video which shares important information on resources available to help prevent the sale of tobacco products to minors. https://t.co/zEzTwjPBoc

These trends, if they continue into 2019 which I believe they are, represent an existential threat to the entire product category. The irresponsible actions of some product developers, allowing this use to continue till now, puts the entire opportunity at risk for adult smokers. https://t.co/PclBnSrQ4M QT @NEJM: )

My note to #FDA colleagues today. For many who are furloughed, and can’t check email, I share it here and on our website. On this day when many will receive no paycheck, we’re reminded of the special mission that binds us together in challenging work and difficult circumstances. https://t.co/SO4pB5Lacq

I'm proud of the work done by FDA’s Generic Drug Program in ensuring Americans have access to high quality, lower cost, safe and effective generics. I’m committed to continuing to advance policies aimed at making it more efficient to bring generic competition to the market. https://t.co/BTAHBtLaSj

In calendar years 2017-2018, #FDA approved or tentatively approved a total of 2,048 generic drugs, with two months in Fall 2018 seeing record-breaking generic drug approval totals. https://t.co/HNXuB2tCCs https://t.co/vkJLkOD4z4

THREAD: Update on Shutdown - Questions are being raised around FDA’s efforts to support device safety during the partial lapse in funding, especially with respect to post-market surveillance. I want to provide some background:

First, I want to reassure everyone that while it’s not business as usual at the agency, we are continuing to prioritize our device safety work both before AND after medical devices come to market.

With respect to post-market efforts, the agency is currently monitoring ALL medical device adverse events it receives, looking for concerns and signals that need to be addressed. If we find issues, we can and will act to protect Americans from imminent threats to health.